Results found: 3

Number of results on page

Search results

Sort By:

Limit search:

Plasma citrulline level as a biomarker for cancer therapy-induced small bowel mucosal damage

100%

Barzał J., Szczylik C., Rzepecki P., Jaworska M., Anuszewska E.

2014

vol. 61

issue 4

615-631

Regimen-related mucosal toxicity is extremely common following cytotoxic chemotherapy and radiotherapy. Mucositis is as an important determinant of the inflammatory response and infectious complications in cancer treated patients. Most assessment scales for mucosal damage are focussed on oral mucositis, since it is easy to evaluate. Measuring gastrointestinal musocal damage objectively remains difficult because it cannot be seen directly or readily detected. One of potential non-invasive biomarkers of gastrointestinal mucosal damage is plasma citrulline level. Citrulline is an amino acid produced by small bowel enterocytes. Low concentration of free circulating citrulline signifies severe intestinal mucosal damage in humans with nonmalignant disorders, such as villous atrophy-associated diseases, short bowel syndrome, Crohn's disease, and is used in follow-up after small bowel transplantation. The plasma citrulline level is a reliable and objective biochemical marker of enterocyte mass and function in humans, and therefore can be used to monitor enterocyte toxicity resulting from chemotherapy and radiotherapy during anticancer therapy in patients with severely disturbed gut integrity.

Sarcomatoid renal-cell carcinoma: treatment strategy, review of the literature and a case report

86%

Gębara-Puchniarz A., Hryciuk B., Stec R., Szczylik C., Grala B., Kozłowski W.

OncoReview

2016

vol. 6

issue 4

A184-187

Introduction: Sarcomatoid renal-cell carcinoma is a very rare cancer characterised with aggressive course of disease and poor prognosis. At present there are no standards of care for this histologic subtype of renal cell carcinoma resistant to various forms of systemic treatment. Methods: The study describes a case of 58 year old woman after left nephrectomy for clear cell carcinoma with sarcomatoid component and after resection of right-kidney tumour for synchronous clear cell carcinoma who received first-line bevacizumab and temsirolimus under the clinical trial, and then second-line chemotherapy based on gemcitabine and doxorubicin and ifosfamide-based third-line chemotherapy. The patient underwent pulmonary metastasectomy twice, and once a metastasectomy for liver metastases. Conclusions: Surgery (including metastases treatment) followed by the systemic chemotherapy seems to be correct option of treatment in patients with renal cell carcinoma with sarcomatoid features. The development of optimum method of systemic treatment requires further prospective randomised trials.

The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients – single centre experience

86%

Kardas J., Buraczewska A., Chrom P., Waśko-Grabowska A., Młot B., Szczylik C.

OncoReview

2017

vol. 7

issue 2

92-97

Introduction: Tyrosine kinase inhibitors (TKI) are the standard of treatment in patients with advanced non-small cell lung cancer (NSCLC) with EGFR (endothelial growth factor receptor) gene activating mutation. Objective: The evaluation of the efficacy and toxicity of TKI drugs in NSCLC patients treated in single centre. Material and methods: NSCLC patients treated with TKI (gefitinib, erlotynib, afatinib) between 2012– 2016 were retrospectively analysed. We evaluated: overall response rate (ORR) which is the sum of complete responses (CR) and partial remissions (PR), progression free survival (PFS), overall survival (OS) and adverse events (AE) according to CTCAE (Common Terminology Criteria for Adverse Events) scale. Results: The study group were 16 patients ORR was 50% (CR: 1, PR: 7). Median PFS and OS was 8,7 and 22,9 months respectively. Adverse events observed mainly in stage 1 and 2 were related to hyponatraemia, hyperbilirubinemia, skin toxicity and mucositis. There was one death reported due to infectious complications. Conclusion: The efficacy and toxicity of TKI in study group were found to be similar to those described in the literature.

Refine search results

2 OncoReview

1 Acta Biochimica Polonica

1 2017

1 2016

1 2014

3 Szczylik C.

1 Anuszewska E.

1 Barzał J.

1 Buraczewska A.

1 Chrom P.

1 Grala B.

1 Gębara-Puchniarz A.

1 Hryciuk B.

1 Jaworska M.

1 Kardas J.

1 Kozłowski W.

1 Młot B.

1 Rzepecki P.

1 Stec R.

1 Waśko-Grabowska A.

Search results

Plasma citrulline level as a biomarker for cancer therapy-induced small bowel mucosal damage

Sarcomatoid renal-cell carcinoma: treatment strategy, review of the literature and a case report

The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients – single centre experience